In acquired TTP, there are high circulating levels of neutralizing antibodies to wild-type ADAMTS13 and physicians often must resort to immediate plasma exchange prior to addressing the underlying causality of TTP. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.